Scientific Results Presented At ECCMID Demonstrate Well-Differentiated Profile of Basilea's Two Phase III Anti-infective Compounds
03. April 2007 01:35 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, April 3, 2007 (PRIME NEWSWIRE) -- New data presented at ECCMID highlight the microbiological and pharmacokinetic profiles of Basilea's (SWX:BSLN) two late-stage drug candidates...
Basilea Announces Rights and Share Offering
09. März 2007 01:20 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, March 9, 2007 (PRIME NEWSWIRE) -- Further information about the press release is available on www.basilea.com.
...
Annual General Meeting of Shareholders of Basilea Pharmaceutica Ltd.
07. März 2007 13:18 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, March 7, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) shareholders approve all Board of Directors' proposals at Annual General Meeting.
Basilea's shareholders...
Basilea Reports Positive Phase III Results for Alitretinoin
19. Februar 2007 01:28 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Feb. 19, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that its placebo-controlled pivotal phase III BACH trial (Benefit of Alitretinoin in Chronic...
Basilea Invites Shareholders to its Ordinary General Meeting 2007
07. Februar 2007 01:46 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Feb. 7, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) invites its shareholders to the Ordinary General Meeting of Shareholders to be held on Wednesday, March 7,...
Basilea Reports 2006 Financial Results
31. Januar 2007 01:48 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland,, Jan. 31, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced 2006 financial results reflecting successful investments in its three phase III drug candidates....
Basilea Announces Positive Top-Line Results On Second Pivotal Phase III Ceftobiprole Trial
10. Januar 2007 01:35 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Jan. 10, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that the second pivotal ceftobiprole phase III study in complicated skin infections met its...
Basilea Announces Start of Phase III Program for Isavuconazole, Its Third Investigational Drug to Reach Pivotal Trials
19. Dezember 2006 01:49 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Dec. 19, 2006 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today the opening of two primary-treatment phase III clinical trials for isavuconazole (BAL8557)...
Basilea to Co-Promote Ceftobiprole
07. Dezember 2006 01:35 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Dec. 7, 2006 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that it has exercised its co-promotion option on ceftobiprole, its investigational anti-MRSA...
Basilea Reports Excellent Pivotal Data for Ceftobiprole, a Novel Anti-MRSA Broad-spectrum Investigational Antibiotic, at ICAAC
29. September 2006 01:39 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Sept. 29, 2006 (PRIMEZONE) -- Ceftobiprole is the first anti-MRSA broad-spectrum cephalosporin to demonstrate efficacy in a large clinical trial in patients infected with...